Tag - MNLO

Developments

Menlo Therapeutics reports positive data from Phase 2 acne vulgaris trial

Menlo Therapeutics (NASDAQ:MNLO) reported positive results from its Phase 2 trial evaluating FCD105 or the treatment of moderate-to-severe acne vulgaris. The study enrolled 447 patients who received either FCD105, a 3%...

June 4, 2020

Developments

Menlo Therapeutics ZILXI gets FDA approval for rosacea

Menlo Therapeutics’ (NASDAQ:MNLO) ZILXI received FDA approval for the treatment of inflammatory lesions of rosacea in adults. The company noted that ZILXI, a minocycline topical foam, is the first minocycline product of...

May 29, 2020

Tag - MNLO

Menlo Therapeutics reports positive data from Phase 2 acne vulgaris trial

Menlo Therapeutics ZILXI gets FDA approval for rosacea

General

More